A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg Positive, Chronic Hepatitis B
Latest Information Update: 08 Jun 2025
At a glance
- Drugs Tenofovir alafenamide (Primary) ; Tenofovir disoproxil fumarate
- Indications Hepatitis B
- Focus Registrational; Therapeutic Use
- Sponsors Gilead Sciences
Most Recent Events
- 03 Jan 2024 New trial record